Clinical Trials Logo

Pancreatic Diseases clinical trials

View clinical trials related to Pancreatic Diseases.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04021264 Withdrawn - Liver Diseases Clinical Trials

The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery

Start date: August 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Major abdominal surgery - like non-laparoscopic bowel resection, liver, gastric, or pancreas surgery - is performed under general anesthesia. Pain control for after the surgery can be achieved purely with intravenous and oral pain medication or in combination with freezing of the nerves. Nerve freezing (nerve block) placed before surgery has the potential to substantially reduce the amount of inhaled anesthetic given to the patient during surgery. This can benefit the patient with being more awake and crisp more quickly after surgery. It can also reduce cost to the system. A further benefit which has received very little attention so far, is that reducing the amount of inhaled anesthetic given also lowers the environmental footprint created by the anesthetic. The investigators of the proposed study plan to quantify the amount of inhaled anesthetic used for each case and will compare how the consumption is affected by whether the epidural block is applied before or after surgery. Patients will have a nerve block catheter (epidural catheter) placed prior to the induction of general anesthetic by an experienced regional anesthesiologist. The epidural catheter will be bolused with a solution to which the anesthesiologist is blinded which will either be local anesthetic or dextrose (sham). The general anesthetic will be conducted according to a the protocol with the aim of maintaining a standard anesthetic depth monitored by patient state index (PSI). Measurements of the MAC-Value (minimum alveolar concentration) of inhaled anesthetic will be recorded every five minutes and will be noted down by a blinded observer. At the end of the case the anesthesiologist blinded to the solution will inject another solution (now a dextrose (sham) or local anesthetic before the patient is woken up.

NCT ID: NCT03598283 Withdrawn - Burns Clinical Trials

Liver, Pancreas and Thyroid Function in Burn Patients

Start date: June 25, 2018
Phase:
Study type: Observational

The purpose of this study is to determine the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid and the pancreas will be assessed via ultrasound (GE Medical Systems, Waukesha, USA) and standard blood parameters, respectively.

NCT ID: NCT00671463 Withdrawn - Pancreatic Cancer Clinical Trials

Pancreatic Stent to Prevent Leak After Distal Pancreatectomy

LEAPS
Start date: April 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate an intervention to prevent complications after pancreas surgery. The goal is to determine if placing a stent into the pancreatic duct before surgery will decrease or prevent leaking from the pancreatic duct after surgery. Leaks are common after pancreas surgery and can result in serious problems and post-operative pain. The study will compare two groups. One group will have the stent before surgery, and the other group will have standard pancreas surgery, no endoscopy, and no stent.

NCT ID: NCT00663975 Withdrawn - Cystic Fibrosis Clinical Trials

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

Start date: February 2009
Phase: N/A
Study type: Interventional

Hypothesis:DCI 1020 capsules are safe and effective in treating exocrine pancreatic insufficiency in CF patients <= 2 years of age. The results of this study are intended to be submitted to the FDA as part of the NDA package for marketing approval of PANCRECARB (DCI 1020).